Actuate Therapeutics (ACTU) vs Vyome (HIND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vyome (HIND) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 65.4% versus a loss of 92.5%. Vyome is the larger company by market cap ($14.7 million vs $14.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | HIND |
|---|---|---|
| Share price | $0.6102 | $2.09 |
| Market cap | $14.65M | $14.67M |
| 1-day change | -10.13% | +2.96% |
| YTD return | -90.03% | -40.99% |
| 1-year return | -92.46% | -65.42% |
| 5-year return | — | -100.00% |
| P/E ratio (TTM) | — | 1.17 |
| EPS (TTM) | $-0.87 | $1.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.49 | $6.56 |
| 52-week low | $0.604 | $1.75 |
| Distance from 52-week high | -92.81% | -68.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1814.13% | +322.49% |
| Average volume | 386.51K | 13.32K |
| Shares outstanding | 24.01M | 7.02M |
| Employees | 12 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HIND has outperformed ACTU by 27.0 percentage points over the past year.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ACTU vs HIND FAQ
Which is bigger, Actuate Therapeutics or Vyome?
Vyome (HIND) is larger, with a market capitalization of $14.67M compared with $14.65M for Actuate Therapeutics (ACTU).
Which stock has performed better over the past year, ACTU or HIND?
HIND returned -65.42% over the past 12 months, compared with -92.46% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Vyome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.